Floatz logo

LBH589

Malignant Melanoma

Dana-Farber Cancer InstitutePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Malignant Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Tebentafusp
Immunocore Ltd
Phase 3BB
uv1
Ultimovacs ASA
Phase 2BB
cyt004-melqbg10
Cytos Biotechnology AG
Phase 2BB
Zelboraf
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

LBH589 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
leukemiaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →